185 related articles for article (PubMed ID: 38473389)
1. Peptide Therapeutics: Unveiling the Potential against Cancer-A Journey through 1989.
Al Musaimi O
Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473389
[TBL] [Abstract][Full Text] [Related]
2. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
3. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
de Visser M; Verwijnen SM; de Jong M
Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
[TBL] [Abstract][Full Text] [Related]
4. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.
Schally AV; Nagy A
Eur J Endocrinol; 1999 Jul; 141(1):1-14. PubMed ID: 10407215
[TBL] [Abstract][Full Text] [Related]
5. Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review).
Sun T; Niu X; He Q; Liu M; Qiao S; Qi RQ
Mol Clin Oncol; 2023 Jun; 18(6):47. PubMed ID: 37206431
[TBL] [Abstract][Full Text] [Related]
6. Stepping forward in antibody-drug conjugate development.
Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ
Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334
[TBL] [Abstract][Full Text] [Related]
7. Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable "click" oxime bond tethers and preclinical evaluation against prostate cancer.
Vrettos EI; Karampelas T; Sayyad N; Kougioumtzi A; Syed N; Crook T; Murphy C; Tamvakopoulos C; Tzakos AG
Eur J Med Chem; 2021 Feb; 211():113018. PubMed ID: 33223264
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and clinical studies of peptide receptor radionuclide therapy.
Pool SE; Krenning EP; Koning GA; van Eijck CH; Teunissen JJ; Kam B; Valkema R; Kwekkeboom DJ; de Jong M
Semin Nucl Med; 2010 May; 40(3):209-18. PubMed ID: 20350630
[TBL] [Abstract][Full Text] [Related]
9. A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads.
Chia CSB
ChemMedChem; 2022 Jun; 17(11):e202200032. PubMed ID: 35384350
[TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy.
Riccardi F; Dal Bo M; Macor P; Toffoli G
Front Pharmacol; 2023; 14():1274088. PubMed ID: 37790810
[TBL] [Abstract][Full Text] [Related]
12. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
[TBL] [Abstract][Full Text] [Related]
13. Antibody-Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence.
Gogia P; Ashraf H; Bhasin S; Xu Y
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568702
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.
Nader-Marta G; Molinelli C; Debien V; Martins-Branco D; Aftimos P; de Azambuja E; Awada A
Ther Adv Med Oncol; 2023; 15():17588359231183679. PubMed ID: 37435563
[TBL] [Abstract][Full Text] [Related]
15. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.
Teplán I
Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357
[TBL] [Abstract][Full Text] [Related]
16. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
17. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
18. Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action.
Ratcliffe KE; Fraser HM; Sellar R; Rivier J; Millar RP
Endocrinology; 2006 Jan; 147(1):571-9. PubMed ID: 16223868
[TBL] [Abstract][Full Text] [Related]
19. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.
Sheyi R; de la Torre BG; Albericio F
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214128
[TBL] [Abstract][Full Text] [Related]
20. Peptide-Drug Conjugate: A Novel Drug Design Approach.
Ma L; Wang C; He Z; Cheng B; Zheng L; Huang K
Curr Med Chem; 2017; 24(31):3373-3396. PubMed ID: 28393694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
